Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 271Breast 166Sarcoma 92Other hematologic neoplasm 70Genitourinary 35Gastrointestinal 34Gynecologic 30CNS 30Plasma cell 22Thoracic 10Head & Neck 9Other solid neoplasm 6Endocrine 6Myeloid 5Tumor-Agnostic 3Dermatologic 3NET 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Doxorubicin × Tumor-Agnostic × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

NCT01031420 2019-09-17

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

Phase 2 Completed
54 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡